Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Editas Medicine Inc's Business Segments
Editas Medicine Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 3
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 3 | 100% |
Description of Editas Medicine Inc's Business Segments
Editas Medicine Inc is a leading biotechnology company that specializes in the development and commercialization of novel gene-editing technologies. The company was founded in 2013 by a group of renowned scientists, including Jennifer Doudna and Feng Zhang, who are pioneers in the field of CRISPR gene editing.
At its core, Editas Medicine aims to leverage its cutting-edge technology to address a wide range of genetic diseases. The company's approach revolves around using CRISPR-based gene editing tools to precisely modify disease-causing genes and restore normal cellular function. This innovative approach holds immense promise for treating a variety of genetic disorders that were previously considered incurable.
One of the key strengths of Editas Medicine lies in its extensive expertise in CRISPR technology. CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a groundbreaking gene-editing technique that allows scientists to precisely make changes to an organism's DNA. Editas has built upon this technology and developed its own proprietary CRISPR-Cas9 platform, which enables highly precise and efficient gene-editing processes.
The company's technology platform and expertise have positioned Editas Medicine as a leader in the rapidly evolving field of gene editing. The applications of this technology span across multiple therapeutic areas, including ophthalmology, neurology, oncology, and rare genetic disorders. Editas is actively involved in several preclinical and clinical programs aimed at developing transformative therapies for various genetic diseases.
Editas Medicine has also established strategic partnerships with leading pharmaceutical companies and research institutions to further accelerate the development and commercialization of its gene-editing technology. These collaborations enable the company to access additional resources, expertise, and funding necessary for advancing its pipeline.
As with any innovative biotechnology company, Editas Medicine faces certain challenges and regulatory uncertainties. The nature of gene editing technology raises ethical concerns, and the company is committed to addressing these issues responsibly and in compliance with regulatory frameworks. It also faces competition from other companies and researchers who are also exploring CRISPR-based gene editing.
Overall, Editas Medicine is at the forefront of the gene-editing revolution, driving advancements in the treatment of genetic diseases. With its cutting-edge technology, strong scientific expertise, and strategic partnerships, the company is well-positioned to continue making significant contributions in the field of gene editing and transform the lives of patients suffering from genetic disorders.
At its core, Editas Medicine aims to leverage its cutting-edge technology to address a wide range of genetic diseases. The company's approach revolves around using CRISPR-based gene editing tools to precisely modify disease-causing genes and restore normal cellular function. This innovative approach holds immense promise for treating a variety of genetic disorders that were previously considered incurable.
One of the key strengths of Editas Medicine lies in its extensive expertise in CRISPR technology. CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a groundbreaking gene-editing technique that allows scientists to precisely make changes to an organism's DNA. Editas has built upon this technology and developed its own proprietary CRISPR-Cas9 platform, which enables highly precise and efficient gene-editing processes.
The company's technology platform and expertise have positioned Editas Medicine as a leader in the rapidly evolving field of gene editing. The applications of this technology span across multiple therapeutic areas, including ophthalmology, neurology, oncology, and rare genetic disorders. Editas is actively involved in several preclinical and clinical programs aimed at developing transformative therapies for various genetic diseases.
Editas Medicine has also established strategic partnerships with leading pharmaceutical companies and research institutions to further accelerate the development and commercialization of its gene-editing technology. These collaborations enable the company to access additional resources, expertise, and funding necessary for advancing its pipeline.
As with any innovative biotechnology company, Editas Medicine faces certain challenges and regulatory uncertainties. The nature of gene editing technology raises ethical concerns, and the company is committed to addressing these issues responsibly and in compliance with regulatory frameworks. It also faces competition from other companies and researchers who are also exploring CRISPR-based gene editing.
Overall, Editas Medicine is at the forefront of the gene-editing revolution, driving advancements in the treatment of genetic diseases. With its cutting-edge technology, strong scientific expertise, and strategic partnerships, the company is well-positioned to continue making significant contributions in the field of gene editing and transform the lives of patients suffering from genetic disorders.
Editas Medicine Inc. is a pioneering biotechnology company dedicated to the development of transformative genome editing therapies. With a strong focus on addressing genetic diseases through innovative approaches, Editas operates across several key segments, each contributing to their mission of revolutionizing medicine through cutting-edge technologies and research.
Segments:
1. Therapeutic Segment:
Editas Medicine is primarily oriented toward the therapeutic segment, which involves the development of gene editing therapies targeting a broad range of genetic disorders. The companys primary goal in this segment is to discover and develop transformative treatments for various debilitating conditions caused by genetic mutations, including inherited retinal diseases, blood disorders, and other genetic conditions.
Products and Services:
1. CRISPR/Cas9 Technology:
Editas Medicine utilizes the groundbreaking CRISPR/Cas9 gene editing technology, which allows for precise modifications of DNA sequences. This technology enables the correction of genetic defects and modification of gene functions, providing a powerful platform for developing potential life-saving therapies. By leveraging this state-of-the-art gene-editing tool, Editas aims to create therapies that can alter the course of genetic diseases.
2. Research Toolkits:
To support the scientific community, Editas Medicine offers comprehensive research toolkits that are essential for conducting genome editing experiments. These kits contain advanced technologies, reagents, and detailed protocols, empowering researchers to effectively explore and implement gene editing techniques in their studies. By providing these resources, Editas fosters innovation and collaboration in the field of genomics.
3. Collaborative Partnerships:
Editas Medicine actively collaborates with various stakeholders, including pharmaceutical companies, academic institutions, and research organizations, to enhance their gene editing capabilities. These partnerships are designed to combine expertise and resources to accelerate the development of new therapies. By fostering a collaborative environment, Editas aims to expedite the translation of scientific discoveries into viable treatment options.
4. Educational Resources:
Understanding the importance of informed engagement, Editas Medicine offers a variety of educational resources, including workshops and informational sessions, designed to promote awareness and understanding of genome editing technologies. These initiatives are intended to educate the scientific community, healthcare professionals, and the general public about the implications and potential of genome editing in improving health outcomes.
5. Pipeline Development:
Editas Medicine maintains a robust pipeline that encompasses a wide array of potential therapies targeting various genetic conditions. The pipeline includes initiatives focused on ocular diseases, such as Leber Congenital Amaurosis (LCA) and other retinal disorders; hematological conditions like sickle cell disease and beta-thalassemia; as well as applications in oncology and neurological diseases. The company is committed to advancing these programs through rigorous preclinical and clinical studies to ensure safe and effective treatments for patients in need.
6. Regulatory Affairs and Manufacturing:
Editas invests significantly in regulatory affairs and manufacturing capabilities to ensure that its therapeutic products meet stringent quality standards and regulatory compliance. This investment is crucial for navigating the complex drug development process. The companys dedication to regulatory excellence and efficient manufacturing processes aims to streamline the path from research to market, ensuring that patients receive safe and effective therapies in a timely manner.
Conclusion:
Editas Medicine Inc. is firmly positioned at the forefront of the biotechnology industry, driven by its commitment to advancing genome editing technologies. Through a comprehensive array of segments, products, and services—including innovative gene editing therapies, essential research toolkits, collaborative partnerships, educational initiatives, a robust drug pipeline, and stringent regulatory practices—Editas is dedicated to revolutionizing the treatment landscape for genetic diseases and pushing the boundaries of genetic medicine.
Segments:
1. Therapeutic Segment:
Editas Medicine is primarily oriented toward the therapeutic segment, which involves the development of gene editing therapies targeting a broad range of genetic disorders. The companys primary goal in this segment is to discover and develop transformative treatments for various debilitating conditions caused by genetic mutations, including inherited retinal diseases, blood disorders, and other genetic conditions.
Products and Services:
1. CRISPR/Cas9 Technology:
Editas Medicine utilizes the groundbreaking CRISPR/Cas9 gene editing technology, which allows for precise modifications of DNA sequences. This technology enables the correction of genetic defects and modification of gene functions, providing a powerful platform for developing potential life-saving therapies. By leveraging this state-of-the-art gene-editing tool, Editas aims to create therapies that can alter the course of genetic diseases.
2. Research Toolkits:
To support the scientific community, Editas Medicine offers comprehensive research toolkits that are essential for conducting genome editing experiments. These kits contain advanced technologies, reagents, and detailed protocols, empowering researchers to effectively explore and implement gene editing techniques in their studies. By providing these resources, Editas fosters innovation and collaboration in the field of genomics.
3. Collaborative Partnerships:
Editas Medicine actively collaborates with various stakeholders, including pharmaceutical companies, academic institutions, and research organizations, to enhance their gene editing capabilities. These partnerships are designed to combine expertise and resources to accelerate the development of new therapies. By fostering a collaborative environment, Editas aims to expedite the translation of scientific discoveries into viable treatment options.
4. Educational Resources:
Understanding the importance of informed engagement, Editas Medicine offers a variety of educational resources, including workshops and informational sessions, designed to promote awareness and understanding of genome editing technologies. These initiatives are intended to educate the scientific community, healthcare professionals, and the general public about the implications and potential of genome editing in improving health outcomes.
5. Pipeline Development:
Editas Medicine maintains a robust pipeline that encompasses a wide array of potential therapies targeting various genetic conditions. The pipeline includes initiatives focused on ocular diseases, such as Leber Congenital Amaurosis (LCA) and other retinal disorders; hematological conditions like sickle cell disease and beta-thalassemia; as well as applications in oncology and neurological diseases. The company is committed to advancing these programs through rigorous preclinical and clinical studies to ensure safe and effective treatments for patients in need.
6. Regulatory Affairs and Manufacturing:
Editas invests significantly in regulatory affairs and manufacturing capabilities to ensure that its therapeutic products meet stringent quality standards and regulatory compliance. This investment is crucial for navigating the complex drug development process. The companys dedication to regulatory excellence and efficient manufacturing processes aims to streamline the path from research to market, ensuring that patients receive safe and effective therapies in a timely manner.
Conclusion:
Editas Medicine Inc. is firmly positioned at the forefront of the biotechnology industry, driven by its commitment to advancing genome editing technologies. Through a comprehensive array of segments, products, and services—including innovative gene editing therapies, essential research toolkits, collaborative partnerships, educational initiatives, a robust drug pipeline, and stringent regulatory practices—Editas is dedicated to revolutionizing the treatment landscape for genetic diseases and pushing the boundaries of genetic medicine.